BOPA 2017 | The adoption of biosimilars in Oxford: a case study

Nicola Stoner

Identifying the optimal means of introducing biosimilars is an issue facing all clinics. Biosimilar rituximab was introduced in Oxford, UK in August 2017. Here, Nicola Stoner, BSc, PhD, MRPharmS, SPresc, IPresc, FCPP from Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses the introduction of biosimilars in Oxford. Dr Stoner details the tools and guidance used for biosimilar adoption, the implementation plan and the multidisciplinary communication required, in addition to the auditing performed. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.

Share this video